Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

AFFiRiS AG: Atherosclerosis Vaccine Development Receives EU Support
The atherosclerosis vaccine development program by AFFiRiS AG is receiving financial support from the EU"s EUROTRANS-BIO call. The respective project is being carried out in cooperation with German company EMC microcollections GmbH. The aim of atherosclerosis vaccination is to increase the amount of "good" high density lipoprotein cholesterol (HDLc) in the blood and thus reduce the occurrence of harmful fatty deposits in the arteries. Product candidates were delivered by AFFiRiS" AFFITOME(R) platform technology. The target is a protein known as CETP (cholesteryl ester transfer protein). Following vaccines for Alzheimer"s disease and Parkinson"s disease, the atherosclerosis vaccine is the third such project announced by AFFiRiS AG.

New National Cancer Standards For Sarcoma Services Published, Wales
New standards to improve access to diagnosis and treatment of sarcomas have been published by the Welsh Assembly Government.
News of the day
In A New Way Of Treating The Flu, Both The H And N Portions Of The Virus Are Targeted
What happens if the next big influenza mutation proves resistant to the available anti-viral drugs? This question is presenting itself right now to scientists and health officials this week at the World Health Assembly in Geneva, Switzerland, as they continue to do battle with H1N1, the so-called swine flu, and prepare for the next iteration of the ever-changing flu virus.
Nutrition

Laparoscopic Radical Versus Partial Nephrectomy For Tumors >4cm: Intermediate-term Oncologic And Functional Outcomes

UroToday.com - Nephron-sparing surgery has become the well-accepted method for treating patients with localized tumor disease of the kidney. Laparoscopic partial nephrectomy (LPN) has evolved such that it is considered equivalent to open partial nephrectomy for tumors 4 cm. They had 110 patients with Stage T1b-T3N0M0 renal cell carcinoma treated with LRN (N=75) or LPN (N=35). As expected the LRN group had larger tumors and more T3a tumors with clear cell pathologic features. The median follow up was 57 months in the LRN group and 44 months in the LPN group. There was no difference between the two treatment groups with regards to overall mortality, cancer-specific mortality, or recurrence rates. However, the LPN group had significantly less reduction in estimated glomerular filtration rate compared to the LRN group. None of the LPN group patients developed second stage chronic kidney disease compared to 12% in the LRN group. Further long term follow up will be necessary to confirm these preliminary findings, but it would appear that even for larger tumors that are organ confined, the nephron-sparing approach is oncologically justified and may be important in maintaining satisfactory renal function. Simmons MN, Weight CJ, Gill IS Urology. 2009 May;73(5):1077-82 10.1016/j.urology.2008.11.059 Written by UroToday.com Contributing Editor Elspeth M. McDougall, MD, FRCSC, MHPE UroToday - the only urology website with original content written by global urology key opinion leaders actively engaged in clinical practice. To access the latest urology news releases from UroToday, go to: www.urotoday.com Copyright © 2009 - UroToday


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009